Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Emory University
Original Assignee
Dana Farber Cancer Institute Inc
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009296392Aexternal-prioritypatent/AU2009296392B2/en
Application filed by Dana Farber Cancer Institute Inc, Emory UniversityfiledCriticalDana Farber Cancer Institute Inc
Priority to AU2013204875ApriorityCriticalpatent/AU2013204875B2/en
Publication of AU2013204875A1publicationCriticalpatent/AU2013204875A1/en
Application grantedgrantedCritical
Publication of AU2013204875B2publicationCriticalpatent/AU2013204875B2/en
Cross-species-specific spcaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxcd3, igf-irxcd3 or fapalphaxcd3 bispecific single chain antibodies, compositions comprising the same and uses thereof